{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:31:31Z","timestamp":1794864691221,"version":"4.9.1"},"reference-count":28,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,1,4]]},"abstract":"<jats:p>Publisher's Note: There is a Blood Commentary on this article in this issue.<\/jats:p>","DOI":"10.1182\/blood-2017-07-793760","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T20:55:22Z","timestamp":1508187322000},"page":"121-130","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":557,"title":["Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy"],"prefix":"10.1182","volume":"131","author":[{"given":"Joshua A.","family":"Hill","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Li","sequence":"additional","affiliation":[{"name":"Juno Therapeutics, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"Hay","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu","family":"Cherian","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley R.","family":"Riddell","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boeckh","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Turtle","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111822282494400_B1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/cpt.392","article-title":"CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies","volume":"100","author":"Turtle","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"2019111822282494400_B2","first-page":"880","article-title":"The promise of chimeric antigen receptor T-cell therapy","volume":"30","author":"Frey","year":"2016","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"2019111822282494400_B3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2016.09.002","article-title":"Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse","volume":"23","author":"Kenderian","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"355","key":"2019111822282494400_B4","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"6","key":"2019111822282494400_B5","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"16","key":"2019111822282494400_B6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111822282494400_B7","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111822282494400_B8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"9967","key":"2019111822282494400_B9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"303","key":"2019111822282494400_B10","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"2019111822282494400_B11","volume-title":"Sci Transl Med","author":"Davila","year":"2014"},{"key":"2019111822282494400_B12","volume-title":"J Clin Oncol","author":"Turtle","year":"2017"},{"issue":"26","key":"2019111822282494400_B13","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111822282494400_B14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111822282494400_B15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.semarthrit.2013.08.001","article-title":"Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums","volume":"43","author":"Navarro","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"2019111822282494400_B16","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2019111822282494400_B17","volume-title":"Biol Blood Marrow Transplant","author":"van Burik","year":"2007"},{"issue":"2","key":"2019111822282494400_B18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbmt.2015.09.013","article-title":"Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors","volume":"22","author":"Young","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111822282494400_B19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00001648-199601000-00006","article-title":"Exact estimates for a rate ratio","volume":"7","author":"Martin","year":"1996","journal-title":"Epidemiology"},{"key":"2019111822282494400_B20","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","author":"Hay","journal-title":"Blood"},{"issue":"9","key":"2019111822282494400_B21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"27","key":"2019111822282494400_B22","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9747","key":"2019111822282494400_B23","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"2019111822282494400_B24","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"24","key":"2019111822282494400_B25","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJM199806113382407","article-title":"Infection in organ-transplant recipients","volume":"338","author":"Fishman","year":"1998","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111822282494400_B26","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111822282494400_B27","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial","volume":"96","author":"Marr","year":"2000","journal-title":"Blood"},{"issue":"4","key":"2019111822282494400_B28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/1\/121\/1367372\/blood793760.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/1\/121\/1367372\/blood793760.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T22:28:38Z","timestamp":1574116118000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/1\/121\/107692\/Infectious-complications-of-CD19targeted-chimeric"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,4]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-07-793760","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732006346.793562632","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,4]]}}}